此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis (Prospec-HIV)

2019年2月15日 更新者:Oswaldo Cruz Foundation

Prospective Evaluation of HIV Infected Patients Followed at Evandro Chagas National Institute of Infectious Disease (INI) - Oswaldo Cruz Foundation (FIOCRUZ) Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis

Human immunodeficiency virus (HIV) infection is a major global health issue with up to 40 million people infected worldwide. Due to highly active antiretroviral therapy, mortality related to acquired immunodeficiency syndrome (AIDS) has been reducing in the last decades. However, liver disease remains as an important cause of severe complications and death.

Hepatic fibrosis progression is the main responsible for liver-related outcomes in HIV-positive patients. Co-infection by hepatitis B (HBV) or hepatitis C virus (HCV) is highly prevalence in HIV patients. Chronic viral co-infection induces faster liver fibrosis progression compared to mono-infected HIV. However, published data have been reporting presence of significant liver fibrosis in HIV without HBV or HCV infection. This might be related to direct action of HIV in hepatocytes or association with others factors, such as non-alcoholic fatty liver disease (NAFLD). NAFLD is associated with metabolic factors, such as obesity and type-2 diabetes mellitus. However, antiretroviral drugs may induce abnormal body fat distribution (lipodistrophy) and insulin resistance playing an important role on this process. Liver biopsy has been historically considered as the gold standard to evaluate liver injury. However, this painful method presents several limitations. Therefore, several non-invasive methods for estimation of liver fibrosis, such as biomarkers (APRI, FIB-4, FibroTest and FibroMeter) and transient elastography by Fibroscan, have been developed as an alternative to liver biopsy. The diagnostic performance and prognostic value of biomarkers and transient elastography have been validated in patients with chronic liver diseases. However, few data are available in HIV patients, especially in those without chronic viral co-infection.

Therefore, patients, medical doctors and scientific community will be beneficiated by the future application of non-invasive methods for estimation of liver injury in clinical practice in HIV patients.

研究概览

详细说明

In HIV-positive patients with or without chronic viral hepatitis co-infection, the primary aims of this project are: (i) to estimate the prevalence and incidence of liver injury (including progression of fibrosis, necro-inflammatory activity and steatosis) and to report the normal values of non-invasive methods in HIV population; (ii) to validate the diagnostic performance of non-invasive methods using a method without a gold standard (Latent Class Analysis); (iii) to validate the prognostic value of non-invasive markers to predict overall mortality and liver-related outcomes and (iv) to correlate liver injury with nutritional status. The secondary aim will be the constitution of a cohort of HIV patients, with or without chronic viral hepatitis co-infection for long-term follow-up of severe outcomes.

This prospective cohort study has been approved by the Local Ethical Committee (CAAE: 32889514.4.0000.5262) and it has been enrolling patients from June 2015 at the Evandro Chagas National Institute of Infectious Diseases - Oswaldo Cruz Foundation (INI - FioCruz), Rio de Janeiro, Brazil. A total of 2,000 patients will be included in this study during the next 5 years. This project aims to report the prevalence and incidence of liver disease in a representative sample of HIV patients with and without chronic viral hepatitis co-infection. In addition, the risk factors associated to presence and progression of liver fibrosis and steatosis will be identified and an innovative non-invasive management for estimation of liver injury in HIV patients will be validated.

Patients have been submitted at the same day to the following procedures: (i) clinical examination (anthropometric and demographic characteristics), (ii) blood sample collection (for blood analysis, calculation of biomarkers and stockage of samples), (iii) transient elastography (with M and XL probes by a single experienced operator (>2,000 examinations) and (iv) nutritional status (bioelectrical impedance and 24h diet recall).

研究类型

观察性的

注册 (预期的)

2000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Rio De Janeiro/RJ
      • Rio de Janeiro、Rio De Janeiro/RJ、巴西、21040-360
        • 招聘中
        • Evandro Chagas National Institute of Infectious Diseases

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Patients infected by HIV with or without chronic viral hepatitis

描述

Inclusion Criteria:

  • HIV infection
  • Age >= 18 years

Exclusion Criteria:

  • Auto-immune hepatitis
  • Primary biliary cirrhosis
  • Primary sclerosing cirrhosis
  • Extra-hepatic cholestasis
  • Acute viral hepatitis
  • Hepatic ischemia
  • Hepatic metastasis

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:队列
  • 时间观点:预期

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Evaluation of stage of fibrosis and grade of steatosis in patients infected by HIV
大体时间:change of fibrosis stage and steatosis grade from baseline at 5 years
Staging of liver fibrosis and quantification of steatosis using non-invasive methods and correlation with risk factors
change of fibrosis stage and steatosis grade from baseline at 5 years

次要结果测量

结果测量
措施说明
大体时间
Prognostic value of non-invasive methods
大体时间:up to 5 years
Evaluation of the prognostic value of non-invasive methods for prediction of severe outcomes and mortality
up to 5 years
Prevalence of liver fibrosis
大体时间:up to 3 years
Estimation of liver fibrosis by non-invasive methods
up to 3 years
Prevalence of liver steatosis
大体时间:up to 3 years
Estimation of liver steatosis by non-invasive methods
up to 3 years
Diagnostic performance of non-invasive methods
大体时间:up to 3 years
Evaluation of diagnostic accuracy (sensitivity and specificity) of non-invasive methods using the Latent Class Analysis
up to 3 years
Nutritional status
大体时间:From date of inclusion until the date of first documented alteration on nutritional status, assessed up to 5 years
Evaluation of the nutritional status by bioelectrical impedance and 24h diet recall
From date of inclusion until the date of first documented alteration on nutritional status, assessed up to 5 years
Progression of liver fibrosis
大体时间:From date of inclusion until the date of first documented progression of liver fibrosis, assessed up to 5 years
Estimation of liver fibrosis by non-invasive methods
From date of inclusion until the date of first documented progression of liver fibrosis, assessed up to 5 years
Progression of liver steatosis
大体时间:From date of inclusion until the date of first documented progression of liver steatosis, assessed up to 5 years
Estimation of liver steatosis by non-invasive methods
From date of inclusion until the date of first documented progression of liver steatosis, assessed up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Valdilea G Veloso, PhD、Oswaldo Cruz Foundation
  • 首席研究员:Beatriz Grinsztejn, PhD、Oswaldo Cruz Foundation

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2015年6月1日

初级完成 (预期的)

2020年5月1日

研究完成 (预期的)

2022年5月1日

研究注册日期

首次提交

2015年8月27日

首先提交符合 QC 标准的

2015年9月2日

首次发布 (估计)

2015年9月4日

研究记录更新

最后更新发布 (实际的)

2019年2月18日

上次提交的符合 QC 标准的更新

2019年2月15日

最后验证

2018年2月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅